Gts Securities LLC Akebia Therapeutics, Inc. Transaction History
Gts Securities LLC
- $45.4 Billion
- Q3 2024
A detailed history of Gts Securities LLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Gts Securities LLC holds 16,500 shares of AKBA stock, worth $29,535. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,500
Previous 10,000
65.0%
Holding current value
$29,535
Previous $10,000
110.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding AKBA
# of Institutions
120Shares Held
54.8MCall Options Held
291KPut Options Held
179K-
Black Rock Inc. New York, NY11.6MShares$20.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$18 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$10.3 Million13.23% of portfolio
-
Geode Capital Management, LLC Boston, MA4.75MShares$8.51 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.72MShares$6.65 Million0.01% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $329M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...